[go: up one dir, main page]

MX2017001900A - Composicion nasal con capacidades de formacion de pelicula. - Google Patents

Composicion nasal con capacidades de formacion de pelicula.

Info

Publication number
MX2017001900A
MX2017001900A MX2017001900A MX2017001900A MX2017001900A MX 2017001900 A MX2017001900 A MX 2017001900A MX 2017001900 A MX2017001900 A MX 2017001900A MX 2017001900 A MX2017001900 A MX 2017001900A MX 2017001900 A MX2017001900 A MX 2017001900A
Authority
MX
Mexico
Prior art keywords
mixture
nasal composition
saline solution
hyaluronic acids
composition
Prior art date
Application number
MX2017001900A
Other languages
English (en)
Other versions
MX377823B (es
Inventor
Saaid Amina
Original Assignee
Church & Dwight Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51383565&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2017001900(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Church & Dwight Co Inc filed Critical Church & Dwight Co Inc
Publication of MX2017001900A publication Critical patent/MX2017001900A/es
Publication of MX377823B publication Critical patent/MX377823B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728Hyaluronic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/14Alkali metal chlorides; Alkaline earth metal chlorides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a una composición nasal que comprende una base salina, un agente activo y una mezcla de un primer ácido hialurónico que tiene un peso molecular máximo de 105 daltons con un segundo ácido hialurónico que tiene un peso molecular de al menos 105 daltons. Dicha composición nasal está indicada para el tratamiento profiláctico o terapéutico de enfermedades de las vías respiratorias superiores, preferiblemente, mediante pulverización o formación de aerosol (spray) de dicha composición a un paciente que lo necesite.
MX2017001900A 2014-08-16 2015-08-05 Composición nasal con capacidades de formación de película. MX377823B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14181205.7A EP2985027B1 (en) 2014-08-16 2014-08-16 Nasal composition comprising mixture of hyaluronic acids and saline solution
PCT/IB2015/001822 WO2016027160A2 (en) 2014-08-16 2015-08-05 Nasal composition with film-forming capacities

Publications (2)

Publication Number Publication Date
MX2017001900A true MX2017001900A (es) 2017-04-27
MX377823B MX377823B (es) 2025-03-11

Family

ID=51383565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017001900A MX377823B (es) 2014-08-16 2015-08-05 Composición nasal con capacidades de formación de película.

Country Status (4)

Country Link
US (1) US20170274006A1 (es)
EP (1) EP2985027B1 (es)
MX (1) MX377823B (es)
WO (1) WO2016027160A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111265590B (zh) * 2020-01-21 2022-03-01 华熙生物科技股份有限公司 一种用于鼻腔喷雾透明质酸冻干制剂及其制备方法和应用
IT202000032243A1 (it) * 2020-12-23 2022-06-23 Fidia Farm Spa Nuovi agenti antivirali

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5166331A (en) 1983-10-10 1992-11-24 Fidia, S.P.A. Hyaluronics acid fractions, methods for the preparation thereof, and pharmaceutical compositions containing same
IE57931B1 (en) 1983-10-11 1993-05-19 Fidia Spa Hyaluronic acid fractions having pharmaceutical activity,methods for preparation thereof,and pharmaceutical compositions containing the same
US5079236A (en) 1987-05-27 1992-01-07 Hyal Pharmaceutical Corporation Pure, sterile, pyrogen-free hyaluronic acid formulations their methods of preparation and methods of use
JPH0232013A (ja) 1988-07-20 1990-02-01 Denki Kagaku Kogyo Kk 点鼻剤
WO1993015744A1 (en) 1992-02-10 1993-08-19 Allergan, Inc. Bimodal molecular weight hyaluronate formulations and methods for using same
IT1271001B (it) 1994-07-26 1997-05-26 Poli Ind Chimica Spa Procedimento di preparazione di acido ialuronico mediante fermentazione con streptococcus
IT1287967B1 (it) 1996-10-17 1998-09-10 Fidia Spa In Amministrazione S Preparazioni farmaceutiche per uso anestetico locale
FR2768630B1 (fr) 1997-09-22 2000-08-04 Ulice Sa Utilisation d'alkyl monoglucosides en tant que vecteurs moleculaires
US20020086852A1 (en) 1998-05-14 2002-07-04 Cantor Jerome O. Method for treating respiratory disorders associated with pulmonary elastic fiber injury
FR2780650B1 (fr) 1998-07-03 2000-09-08 Goemar Lab Sa Solutions salines, leur procede de preparation et medicaments a base de ces solutions
US6004560A (en) 1998-11-16 1999-12-21 Hsu; Wu-Ching Nasal spray (drop) for treating fever/cold, and its preparation
US20050232868A1 (en) 1999-10-19 2005-10-20 The Procter & Gamble Company Methods of entrapping, inactivating, and removing viral infections by the administration of respiratory tract compositions
DE10161110A1 (de) 2001-12-12 2003-06-26 Ursapharm Arzneimittel Gmbh Pharmazeutische Zusammensetzung zur ophthalmologischen und rhinologischen Anwendung
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
US7060691B2 (en) 2002-10-10 2006-06-13 Giuseppe Petrigni Pharmaceutical colloidal preparation useful in the treatment of respiratory diseases
FR2847818B1 (fr) 2002-11-28 2008-04-04 Agro Ind Rech S Et Dev Ard Composition pharmaceutique a base d'acide hyaluronique
DE20318634U1 (de) 2003-11-13 2004-02-26 Maria Clementine Martin Klosterfrau Vertriebsgesellschaft Mbh Pharmazeutische Zusammensetzung zur Behandlung von Rhinitiden
EP1718315A4 (en) 2004-02-06 2008-08-13 Univ Monash HIGH DOSE USE OF SULFATED POLYSACCHARIDES IN SHORT INTERVALS FOR THE TREATMENT OF INFECTIONS
US20050224201A1 (en) 2004-04-08 2005-10-13 Kimberly-Clark Worldwide, Inc. Treated crimped multi-ply product
US8642564B2 (en) 2004-08-25 2014-02-04 Aegis Therapeutics, Llc Compositions for drug administration
GB0426068D0 (en) 2004-11-29 2004-12-29 Passion For Life Healthcare Lt Composition with bacteria blocking action
US7524510B2 (en) 2005-02-23 2009-04-28 The Uab Research Foundation Alkyl-glycoside enhanced vaccination
GB0602325D0 (en) 2006-02-06 2006-03-15 Remedy Res Ltd Virucidal compositions and uses
ITMI20060742A1 (it) 2006-04-13 2007-10-14 Patrizia Pattini Composizioni antibatteriche per il trattamento di infezioni delle alte e basse via aeree
US20090326193A1 (en) 2006-06-23 2009-12-31 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
FR2915389B1 (fr) 2007-04-26 2012-12-21 De La Mer Laboratoire Utilisation de solutions ioniques isoosmotiques a base d'eau de mer pour la fabrication de dispositifs medicaux pour la prevention des complications du rhume courant
CN101317847B (zh) 2007-06-06 2010-10-13 深圳市瑞谷医药技术有限公司 一种眼用或耳鼻用药物组合物及其用途
KR101449687B1 (ko) 2008-03-13 2014-10-14 주식회사 바이오랜드 저분자 및 고분자 히알루론산과 유근피로부터 분리된다당체 추출물을 함유하는 노화방지용 조성물
DE102011010668A1 (de) 2011-02-08 2012-08-09 Ursapharm Arzneimittel Gmbh Wässrige pharmazeutische Zusammensetzung zur Prävention und/oder Therapie allergisch gereizter Nasenschleimhaut und dessen Verwendung
PT2543357T (pt) 2011-07-07 2018-04-30 Holy Stone Healthcare Co Ltd Resumo
FR2977494B1 (fr) 2011-07-08 2013-08-16 Ayawane Compositions cosmetiques ou pharmaceutiques contenant des acides hyaluroniques de masses moleculaires differentes
ES2665254T3 (es) 2011-07-12 2018-04-25 Holy Stone Healthcare Co., Ltd. Composiciones que comprenden ácido hialurónico para tratamiento y prevención de enfermedades relacionadas con las mucosas
US20130039950A1 (en) 2011-08-09 2013-02-14 Church & Dwight Co., Inc. Neti-pot packet mixture
CN105792835B (zh) 2013-12-03 2022-03-25 格罗力马托斯国际有限公司 离子水性组合物

Also Published As

Publication number Publication date
EP2985027A1 (en) 2016-02-17
WO2016027160A2 (en) 2016-02-25
EP2985027B1 (en) 2021-03-31
MX377823B (es) 2025-03-11
WO2016027160A3 (en) 2016-04-14
US20170274006A1 (en) 2017-09-28

Similar Documents

Publication Publication Date Title
CY1122189T1 (el) Ιονικες υδατικες συνθεσεις
MX392668B (es) Composiciones nasales de cannabidiol
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX387277B (es) Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
EA201791916A1 (ru) 2'-замещенные карбануклеозидные аналоги для противовирусного лечения
BR112012027055A8 (pt) agente estabilizante para proteínas farmacêuticas.
MX2016004316A (es) Inhalador de polvo seco.
BR112015011497A2 (pt) composto, formulação farmacêutica, produto de combinação, e, método de tratamento de uma doença
MX2018003569A (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
BR112015017525A2 (pt) peptídeo modificado, sal de um peptídeo modificado, medicamento, e, métodos para tratar ou aliviar uma doença cardiovascular e para produzir um peptídeo modificado
MX377175B (es) Solucion para inhalacion de tiotropio, administrada en forma nebulizada y el uso de la misma para tratar enfermedad pulmonar obstructiva crónica (epoc).
BR112015026053A2 (pt) composição farmacêutica, recipiente vedado, inalador dosimetrado, e, métodos para tratamento de um paciente sofrendo ou susceptível a sofrer de um distúrbio respiratório e para fabricação de uma composição farmacêutica
BRPI0915119B8 (pt) uso de iota carragenano
BR112015014174A2 (pt) composição de vacina para indivíduos virgens
FI3848028T3 (fi) Okulaaristen sairauksien hoitomenetelmiä
EA201692278A1 (ru) Комбинации формотерола и будесонида для лечения хобл
RU2017125688A (ru) Антивирусная фармацевтическая композиция
MX2017001900A (es) Composicion nasal con capacidades de formacion de pelicula.
BR112015022134A2 (pt) composto, composição farmacêutica, adesivo, bastão, dispensador de spray, tubo ou caneta, e, método de tratamento de uma infecção
EA202090164A1 (ru) Изотретиноиновые перорально-слизистые композиции и способы их применения
MX2017001899A (es) Composicion nasal que tiene propiedades antivirales.
RU2018118986A (ru) Фармацевтическая композиция для введения в слизистую носа
BR112017022390A2 (pt) composição farmacêutica
BR112015028334A2 (pt) agente e método para o tratamento de herpes
MX383214B (es) COMPOSICIONES Y MÉTODOS DE USO DE ß-HIDROXI-ß-METILBUTIRATO (HMB) PARA AUMENTAR LA RECUPERACIÓN DE TRAUMA DE TEJIDO BLANDO.